A
Andrew Fraser
Researcher at Aberdeen Royal Infirmary
Publications - 61
Citations - 1429
Andrew Fraser is an academic researcher from Aberdeen Royal Infirmary. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 18, co-authored 55 publications receiving 1230 citations. Previous affiliations of Andrew Fraser include Woolmanhill Hospital.
Papers
More filters
Journal ArticleDOI
Hepatitis B prevention, diagnosis, treatment and care: a review
TL;DR: Post-exposure prophylaxis (PEP) with HBV vaccine +/- hepatitis B immunoglobulin is highly effective in preventing mother to child transmission and in preventing transmission following sharps injuries, sexual contact and other exposures to infected blood and body fluids.
Journal ArticleDOI
Helicobacter pylori is killed by nitrite under acidic conditions
TL;DR: The antimicrobial effect of nitrite at pH 2 against H pylori was dose dependent and complete kill of organisms occurred at concentrations ⩾500 μmol/l, which should prompt further research into the effect of salivary nitrite on the survival of H plyori in the human stomach.
Journal ArticleDOI
Nicorandil associated anal ulceration.
TL;DR: Nicorandil-associated anal ulceration should be considered in the differential diagnoses of nonhealing anal ulcers.
Journal ArticleDOI
Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes
Hamish Innes,Hamish Innes,Scott A. McDonald,Scott A. McDonald,John F. Dillon,Sam Allen,Peter C. Hayes,David J. Goldberg,David J. Goldberg,Peter R. Mills,Stephen T. Barclay,David Wilks,Heather Valerio,Heather Valerio,Ray Fox,Diptendu Bhattacharyya,Nicholas A. Kennedy,J. Morris,Andrew Fraser,Adrian J. Stanley,Peter Bramley,Sharon J. Hutchinson,Sharon J. Hutchinson +22 more
TL;DR: Overall, SVR is associated with reduced hazard for a range of hepatic and nonhepatic events; an association between SVR and behavioral events is consistent with SVR patients leading healthier lives; and the short‐term value of SVR was greatest for those with nonmild disease.
Journal ArticleDOI
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
Prakash Ramachandran,Andrew Fraser,Kosh Agarwal,Andrew Austin,Ashley Brown,Graham R. Foster,Ray Fox,Peter C. Hayes,Clifford Leen,Peter R. Mills,David Mutimer,S.D. Ryder,John F. Dillon +12 more
TL;DR: The nonstructural 3 serine protease inhibitors, boceprevir and telaprevir, represent the first in a new generation of directly acting antivirals against genotype 1 hepatitis C (HCV) infection that will increase the complexity of therapeutic regimens, the rates of side‐effects and costs.